Clinical efficacy issues in the treatment of multiple sclerosis: Update of natalizumab

ClinicoEconomics and Outcomes Research

Volumn 1, Issue 1, 2009, Pages 45-51

  Patti, Francesco ^a,b   Pappalardo, Angelo ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b Acireale Hospital   (Italy)

Author keywords

Disease modifying drugs; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB;

ALLERGY; BRAIN DAMAGE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EXPERIMENTAL MODEL; FATIGUE; GASTROENTERITIS; HEADACHE; HUMAN; LUNG ASPERGILLOSIS; MULTIPLE SCLEROSIS; NAUSEA; PHARYNGITIS; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; VIRUS MENINGITIS;

EID: 77953419641     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/ceor.s6665     Document Type: Review

References (53)

1. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain. 1989;112:133-146.
2. Lyon-Caen O, Jouvent R, Hauser S, et al. Cognitive function in recentonset demyelinating diseases. Arch Neurol. 1986;43:1138-1141.
3. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol. 1992;49(12):1237-1242.
4. Benito-León J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on health-related quality of life. Disab Rehabil. 2003;25(23):1291-1303.
5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: clinical results of a multicenter randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM; the Multiple Sclerosis Collaborativ Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing-remitting multiple sclerosis. Ann Neurol. 1996;39:285-294.
7. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improve disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter double-blind placebo controlled trial. Neurology. 1995;45:1268-1276.
8. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498-1504.
9. Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L. The therapy of multiple sclerosis with immune-modulating or immunosupressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clin Neurol Neurosurg. 2008;110: 878-885.
10. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;61:1332-1338.
11. Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008;79(1):52-56.
12. Vollmer T, Campagnolo D, Panitch P, Bar-Or A, Arnold D. Reductions in MRI Disease activity and relapse rates observed after induction of short-term immunosuppression with mitoxantrone followed by long-term glatiramer acetate (GA) are maintained at 24 months in patients with relapsing remitting multiple sclerosis (RRMS). Neurology. 2007;68(Suppl 1):A279.
13. Deutsch F, Arnold DL. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008;14: 663-670.
14. Golg R. Combination therapies in multiple sclerosis. J Neurol. 2008;255(Suppl 1):51-60.
15. Hynes RO. Integrins: a family of cell surface receptors. Cell. 1987;48:549-554.
16. French-Constant C. Pathogenesis of multiple sclerosis. Lancet. 1994;343:271-275.
17. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992; 356(6364):63-66.
18. Kent SJ, Karlik SJ, Cannon C, et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol. 1995;58(1):1-10.
19. Tubridy N, Behan PO, Capildeo R; UK Antegren Study Group. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology. 1999;53:466-472.
20. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15-23.
21. O'Connor PW, Goodman A, Willmer-Hulme AJ; the Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses Clinical and MRI effects. Neurology. 2004;62:2038-2043.
22. Goodman AD, Rossman HS, Bar-Or A, et al. GLANCE: Results pf a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806-812.
23. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
24. Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911-923.
25. Calabresi PA, Giovannoni G, Confavreux C, et al; AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69:1391-1403.
26. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology. 2003;60:634-639.
27. Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003;98:2372-2382.
28. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268-274.
29. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
30. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353: 1912-1925.
31. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924-933.
32. Center for Drug Evaluation and Research (CDER). Peripheral and Central Nervous System Drugs Advisory Committee; FDA Advisory Hearing, March 7-8, 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/ 06/slides/2006-4208S1-Slide- Index.htm. Accessed on August 14, 2009.
33. National Multiple Sclerosis Society Research Bulletin. Update on Tysabri and PML. June 30, 2009. Available from http://www. nationalmssociety.org/news/ news-detail/. Accessed on July 10, 2009.
34. Bozie C, Belcher G, Kim R, et al. Natalizumab in patients with relapsing-remitting multiple sclerosis: updated utilization and safety results including TOUCH and TYGRIS. Seattle, WA: 61st annual Meeting of American Academy of Neurology; April 25-May 2 2009.
35. Dorsey ER, Thompson JP, Noyes K, et al. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology. 2007;68:1524-1528.
36. Thompson JP, Noyes K, Dorsey ER, et al. Quantitative risk-benefit analysis of natalizumab. Neurology. 2008;71:357-364.
37. Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26(7):617-627.
38. Kobelt G, Berg J, Lindgren P, et al. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler. 2008;14:679-690.
39. Mancardi GL, Amato MP, D'Alessandro R, et al. Natalizumab: a country-based surveillance program. Neurol Sci. 2008;29: S235-S237.
40. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68:1299-1304.
41. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260.
42. Centonze D, Furlan R, Gasperini C, et al. Early relapses after the first dose of natalizumab in active multiple sclerosis patients. Mult Scler. 2008;14:1137-1138.
43. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS. Neurology. 2008;70:1150-1151.
44. O'Connor PW, Goodman A, Kappos L, et al. Results of clinical and magnetic resonance imaging analyses following cessation of natalizumab dosing in patients with multiple sclerosis. Madrid, Spain: 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Sept 29, 2006.
45. Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72:396-401.
46. National Multiple Sclerosis Society. Details: No rebound in those who stopped taking tysabri after extended exposure. Feb 10, 2009. Available from: http://www.nationalmssociety.org/news/news-detail/index. aspx?nid=814. Accessed July 10, 2009.
47. Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J. Natalizumab use in pediatric multiple sclerosis patients. Arch Neurol. 2008;65(12):1655-1658.
48. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessment of disability in multiple sclerosis. BMJ. 1997;314:1580-1583.
49. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11): 1444-1452.
50. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999;5(4): 244-250.
51. Patti F. Cognitive impairment in multiple sclerosis. Mult Scler. 2009;15(1):2-8.
52. Rudick RA, Miller D, Hass S, et al; AFFIRM and SENTINEL Investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62(4):335-346.
53. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol. 2007;102(12):2737-2746.